Molecular Mechanism behind Platinum Associated Chemotherapy-Induced Peripheral Neuropathy (CIPN)
A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Neurobiology".
Deadline for manuscript submissions: 30 July 2024 | Viewed by 465
Special Issue Editor
Interests: oxidative and nitrosative stress; chemotherapy; dose limiting toxicity; superoxide dismutase (SOD) mimetics; chelation therapy
Special Issue Information
Dear Colleagues,
When it comes to the dose-limiting toxicity of chemotherapy, Platinum-Associated Chemotherapy-Induced Peripheral Neuropathy (PA-CIPN) represents one of the most troublesome obstacles in achieving the optimal tumoricidal efficacy of cisplatin and oxaliplatin.
Various approaches for preventing/treating this dose-limiting toxicity caused by cisplatin and oxaliplatin have failed. However, recent clinical studies have shown that Sodium ThioSulfate (STS) may reduce ototoxicity without lowering the tumoricidal efficacy of cisplatin in pediatric patients with localized solid tumors, renewing the possibilities of using a similar approach when it comes to PA-CIPN.
The obstacles that need to be overcome for finding an effective treatment of PA-CIPN apparently involve a lack of consensus around how to quantify CIPN and the use of mainly subjective measures, i.e., various physician- and patient-judged quantifications. Therefore, it is essential to develop objective methods to quantify CIPN.
The exact mechanism behind PA-CIPN is poorly understood. However, it seems reasonable to assume that it is the uptake and the retention of Pt2+ in the peripheral sensory nerve system that cause the toxicity. This system lacks a blood–brain barrier, a draining lymph system, and cerebrospinal fluid. This causes potentially dangerous substances, such as chemotherapy drugs, to accumulate in the peripheral nerve system, leading to oxidative stress and detrimental nerve injuries.
A better mechanistic understanding of PA-CIPN would of course increase the possibility of preventing/treating this bothersome toxicity, without lowering the tumoricidal efficacy of the drugs. We welcome submissions involving studies on key molecules and updates on treatments to avoid or to reduce Chemotherapy-Induced Peripheral Neuropathy.
Dr. Jan Olof G Karlsson
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- Platinum-Associated Chemotherapy-Induced Peripheral Neuropathy (PA-CIPN)
- molecular mechanisms
- pharmacological approach
- objective quantification measures